Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Lysophosphatidic acid (LPA) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 25/November/2017, 3.45 pm

 Natural product Lifespan extension therapy: Magnolol, found in  Houpu magnolia, increases life span via up-regulation of its target gene BubR1, 24/November/2017, 11.18 pm
November 24, 2017
Natural product-derived therapy for Myocardial Infarction: Hypaphorine, isolated from Caragana korshinskii Kom, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via  up-regulation of PNUTS,  25/November/2017, 3.55 pm
November 25, 2017
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


 

From research findings to Therapeutic opportunity:

Lysophosphatidic acid (LPA), by increasing the expression of its target gene, it may (1) promote degradation of HMGCR; and (2) suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing Lysophosphatidic acid (LPA) or its analogues, either alone or in combination with other drugs” may be used to treat NAFLD.

[easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how Lysophosphatidic acid (LPA) decreases the expression of HMGCR to prevent progression to NAFLD.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Lysophosphatidic acid (LPA) decrease the expression of HMGCR to prevent progression of NAFLD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Lysophosphatidic acid (LPA) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 25/November/2017, 3.45 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.